TABLE 1

Study population and anidulafungin treatmenta

PatientSexAge (yr)Body wt (kg)Main diagnosis(es)CVVHDay(s) of anidulafungin treatmentCumulative dose(s) (mg)Sampling procedure
1F2844Sepsis, CF, liver failure, peritoneal mesothelioma+1200Ascites drain
2F6885Ileus, NHL111,200Ascites drain
3M6052AIDS, sepsis, liver cirrhosis+2200Ascites drain
4M6871Liver failure, septic shock3, 6300, 700Paracentesis, ascites drain
5M6561Liver cirrhosis, pneumonia+51,000Paracentesis
6M6061Septic shock, MODS+2200Paracentesis
7F4860Sharp syndrome, sepsis7, 21600, 2,000Paracentesis, thoracentesis
8F5945Liver cirrhosis172,000Pleural drain
9M7369Sepsis, pneumonia+4, 7500, 800Thoracentesis, pleural drain
10M7580AML, MOF+121,300Thoracentesis
  • a CVVH, renal replacement therapy by continuous veno-venous hemofiltration; F, female; M, male; CF, cystic fibrosis; NHL, non-Hodgkin lymphoma; MODS, multiorgan dysfunction syndrome; AML, acute myeloid leukemia; MOF, multiorgan failure.